Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBI-1000
- Development stage
- Preclinical
- Lead developer
- Replicate Bioscience
- Modality
- mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Administration
- Intramuscular
01
Overview
**RBI-1000** is a preclinical self-replicating RNA (srRNA) immunotherapy developed by Replicate Bioscience for estrogen receptor-positive (ER+) breast cancer. It targets acquired resistance mutations and amplifications in ESR1, PIK3CA/PI3K, ERBB2/HER2, and ERBB3/HER3 that emerge following standard-of-care endocrine therapies. The srRNA platform elicits robust CD4+ and CD8+ T cell responses, leading to significant tumor growth inhibition and improved survival in mouse models at doses 100-fold lower than linear mRNA approaches, with plans for clinical advancement in 2024.[3][4][6]
02
Targets
ESR1 (ERα)PIK3CA (Phosphoinositide 3-kinase alpha)ERBB2 (Erb-b2 receptor tyrosine kinase 2)ERBB3 (Erb-b2 receptor tyrosine kinase 3)
Beyond the preview
Go deeper on RBI-1000.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBI-1000.